Dupont Capital Management Corp Has $14.19 Million Holdings in Eli Lilly and Company $LLY

Dupont Capital Management Corp lessened its stake in Eli Lilly and Company (NYSE:LLY) by 8.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,202 shares of the company’s stock after selling 1,725 shares during the quarter. Eli Lilly and Company accounts for about 1.5% of Dupont Capital Management Corp’s investment portfolio, making the stock its 17th biggest holding. Dupont Capital Management Corp’s holdings in Eli Lilly and Company were worth $14,189,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. PNC Financial Services Group Inc. boosted its holdings in shares of Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company’s stock valued at $83,669,349,000 after buying an additional 50,002,551 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company’s stock valued at $65,432,218,000 after buying an additional 4,975,395 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Eli Lilly and Company by 0.6% in the first quarter. Wellington Management Group LLP now owns 12,707,512 shares of the company’s stock valued at $10,495,261,000 after buying an additional 81,587 shares during the period. Goldman Sachs Group Inc. boosted its holdings in shares of Eli Lilly and Company by 13.3% in the first quarter. Goldman Sachs Group Inc. now owns 5,821,993 shares of the company’s stock valued at $4,808,443,000 after buying an additional 682,203 shares during the period. Finally, Nuveen LLC bought a new stake in shares of Eli Lilly and Company in the first quarter worth $4,613,912,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the stock. Leerink Partners reissued a “market perform” rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, August 7th. Deutsche Bank Aktiengesellschaft cut their price objective on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a research report on Monday, August 11th. Hsbc Global Res raised shares of Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 27th. Leerink Partnrs lowered shares of Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 7th. Finally, BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $938.61.

Insider Activity

In other news, CEO David A. Ricks purchased 1,632 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company’s stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gabrielle Sulzberger purchased 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $641.18 per share, for a total transaction of $75,018.06. Following the completion of the transaction, the director directly owned 2,703 shares of the company’s stock, valued at approximately $1,733,109.54. This represents a 4.52% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $808.88 on Tuesday. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm’s fifty day moving average price is $756.56 and its two-hundred day moving average price is $766.20. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63. The firm has a market capitalization of $765.57 billion, a P/E ratio of 52.87, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The firm had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm posted $3.92 earnings per share. The company’s quarterly revenue was up 37.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.